THURSDAY, May 15 (HealthDay News) -- The drug ustekinumab has been shown to be a very effective initial and long-term treatment for moderate-to-severe psoriasis in two studies published in this week's issue of The Lancet.
Ustekinumab works by binding to two interleukins, proteins produced by the immune system that mediate inflammatory reactions in diseases like psoriasis. The binding stops the interleukins from reaching their specific receptors on the surface of cells.